Clovis Oncology Inc (CLVS) Holdings Trimmed by Tocqueville Asset Management L.P.
Tocqueville Asset Management L.P. trimmed its position in Clovis Oncology Inc (NASDAQ:CLVS) by 34.1% during the 4th quarter, Holdings Channel reports. The firm owned 54,780 shares of the biopharmaceutical company’s stock after selling 28,355 shares during the period. Tocqueville Asset Management L.P.’s holdings in Clovis Oncology were worth $3,725,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of CLVS. Capital Analysts LLC acquired a new position in shares of Clovis Oncology in the 3rd quarter worth approximately $111,000. Cypress Capital Management LLC WY lifted its holdings in shares of Clovis Oncology by 272.7% in the 3rd quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 1,500 shares during the last quarter. Commonwealth Equity Services Inc acquired a new position in shares of Clovis Oncology in the 3rd quarter worth approximately $239,000. First Republic Investment Management Inc. acquired a new position in shares of Clovis Oncology in the 3rd quarter worth approximately $251,000. Finally, BB&T Securities LLC acquired a new position in shares of Clovis Oncology in the 3rd quarter worth approximately $288,000.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $64.16, for a total value of $192,480.00. Following the sale, the insider now directly owns 182,583 shares of the company’s stock, valued at approximately $11,714,525.28. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Thorlef Spickschen sold 4,500 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $60.00, for a total transaction of $270,000.00. Following the completion of the sale, the director now directly owns 16,618 shares in the company, valued at $997,080. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,500 shares of company stock worth $1,371,210. 12.50% of the stock is owned by insiders.
Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Monday, February 26th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.25. Clovis Oncology had a negative net margin of 624.02% and a negative return on equity of 81.34%. The firm had revenue of $17.04 million for the quarter, compared to the consensus estimate of $19.42 million. During the same period in the prior year, the firm earned ($1.83) EPS. The firm’s revenue for the quarter was up 21746.2% on a year-over-year basis. equities analysts forecast that Clovis Oncology Inc will post -4.75 earnings per share for the current year.
Several brokerages have recently commented on CLVS. BidaskClub lowered shares of Clovis Oncology from a “sell” rating to a “strong sell” rating in a report on Friday, February 9th. Leerink Swann restated an “outperform” rating and issued a $90.00 price objective (down from $107.00) on shares of Clovis Oncology in a report on Wednesday, November 15th. JPMorgan Chase & Co. restated a “buy” rating on shares of Clovis Oncology in a report on Thursday, January 11th. SunTrust Banks decreased their price objective on shares of Clovis Oncology from $95.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Finally, Cann restated a “hold” rating on shares of Clovis Oncology in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $87.84.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology Inc (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.